Can Dupixent Be a Gamechanger in the Atopic Dermatitis Treatment Landscape?
Dupixent (dupilumab) is a non-immunosuppressive, fully human monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation — a major contributor to Atopic Dermatitis, Asthma, and Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP). How Is Dupixent…
